Introduction
The majority of nosocomial infections in Taiwan hospitals are caused by Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, and various species of Enterobacteriaceae.
1 Among these Gramnegative bacteria causing nosocomial infections, resistance to b-lactam and other antimicrobial agents has increased. 1 Carbapenems have become one of the most important agents for treating infections caused by these multidrug resistance Gram-negative bacteria. 2 Doripenem was approved use in Taiwan in August 2009. Before that, imipenem/cilastatin and meropenem were the only two antipseudomonal carbapenems available in Taiwan.
Studies in other countries have demonstrated doripenem to have similar in vitro activity to meropenem against a wide range of Gram-negative pathogens and to imipenem against Gram-positive pathogens. 3, 4 Doripenem has also been shown to have good activities against extended-spectrum b-lactamase (ESBL) and AmpC producing Enterobacteriaceae 5e7 as well as to P. aeruginosa 8, 9 . It also has limited ability in the selection of resistant strains in vitro. 6, 10, 11 Doripenem has been approved in the United States, European Union, and Taiwan for the treatment of complicated urinary tract and intra-abdominal infections.
12,13 Doripenem has also been approved for a wide range of infections in Japan 14 and for nosocomial pneumonia in the European Union. 13 However, the clinical experience of using doripenem to treat infections caused by multidrug-resistant pathogens and data on its in vitro activities against multidrug-resistant pathogens remained limited in Taiwan. 15 The study was designed to compare the in vitro activities of doripenem and other antimicrobial agents including imipenem and meropenem, against drug-resistant Gramnegative pathogens isolated in a medical center in Taiwan.
Materials and methods

Bacterial isolates
A total of 400 nonduplicate nosocomial blood isolates isolated in 2009, including P. aeruginosa (n Z 100), A. a The susceptible breakpoints were: ceftazidime, 8 mg/mL; doripenem, 2 mg/mL; imipenem, 4 mg/mL; meropenem, 4 mg/mL; amikacin, 16 mg/mL; ciprofloxacin, 1 mg/mL; colistin, 2 mg/mL.
b The susceptible breakpoints were: ceftazidime, 8 mg/mL; doripenem, 1 mg/mL; imipenem, 4 mg/mL; meropenem, 4 mg/mL; amikacin, 16 mg/mL; ciprofloxacin, 1 mg/mL; colistin, 2 mg/mL; tigecycline, 2 mg/mL. 
Antimicrobial susceptibility test
In vitro susceptibilities to various antimicrobial agents of all enrolled bacterial isolates were determined by minimum inhibitory concentrations (MICs) using Etest (AB bioMérieux, Marcy-l'Etoile, France). The tested antibiotics included doripenem, imipenem, meropenem, ciprofloxacin, ceftazidime, amikacin, colistin, and tigecycline. The methodology used for susceptibility testing was direct colony suspension, according to the manufacturer's instructions. P. aeruginosa ATCC 27853 and Escherichia coli ATCC 25922 were used for quality control in each run of test.
The susceptibility test results of ceftazidime, imipenem, meropenem, amikacin, ciprofloxacin, and colistin were interpreted using the criteria provided by the Clinical and Laboratory standards Institute (CLSI), 2010. 19, 20 For tigecycline, we applied the criteria suggested by the US Food and Drug Administration (US-FDA) for Enterobacteriaceae (susceptibility 2 mg/mL ) to A. baumannii.
The susceptibility of doripenem for Enterobacteriaceae was also interpreted using the CLSI criteria. 20 However, CLSI dose not provide interpretive criteria on doripenem for P. aeruginosa and A. baumannii, hence, the US-FDA criteria were used (susceptibility 2 mg/mL for P. aeruginosa and 1 mg/mL for A. baumannii). In this study, carbapenem resistance was defined as resistance to either doripenem, imipenem, or meropenem.
Results
The MIC distributions of and susceptibilities to the eight tested antimicrobial agents against the 400 isolates are shown in Table 1 (P. aeruginosa and A. baumannii) and Table 2 (Enterobacteriaceae). For the 100 isolates of P. aeruginosa, the proportion of carbapenem resistance was 15%. Among the carbapenem-resistant P. aeruginosa, the susceptibility rates of ceftazidime, amikacin, ciprofloxacin, and colistin were 53.3%, 80%, 60%, and 93.3%, respectively.
For the 100 isolates of A. baumannii, the proportion of carbapenem resistance was 44%. Among the carbapenemresistant A. baumannii, the susceptibility rates of ceftazidime, amikacin, ciprofloxacin, tigecycline, and colistin were 18.2%, 18.2%, 20.5%, 70.5%, and 100%, respectively.
Among the Enterobacteriaceae nonsusceptible to ceftazidime, the susceptibility rates of doripenem, imipenem, meropenem, tigecycline, and colistin were 100%, 97.5%, 100%, 92.5%, and 95%, respectively ( Table 2) .
The cumulative MIC distributions of three tested carbapenems for P. aeruginosa, A. baumannii and Enterobacteriaceae are plotted in Figs. 1. Fig. 1A and C showed a similar trend of the MIC distributions of doripenem and meropenem against P. aeruginosa and Enterobacteriaceae, while the MIC distributions curve of imipenem showed a rightward shift indicating a higher MIC distribution. Fig. 1B shows the nearly overlapping MIC distributions curves of doripenem, meropenem and imipenem against A. baumannii (a similar MIC distribution).
Comparisons of the susceptibility rates and nonsusceptibility rates of P. aeruginosa, A. baumannii, and Enterobacteriaceae between doripenem and imipenem are shown in Table 3 . The susceptibility rates and nonsusceptibility rates of P. aeruginosa, A. baumannii, and Enterobacteriaceae between doripenem and imipenem were similar. Comparisons of the susceptibility rates and nonsusceptibility rates of P. aeruginosa, A. baumannii, and Enterobacteriaceae between doripenem and meropenem are shown in Table 4 . The kappa values of these comparisons were 0.905, 0.918, and >0.999, respectively. The susceptibility rates and non-susceptibility rates of P. aeruginosa, A. baumannii, and Enterobacteriaceae between doripenem and meropenem were also similar.
Discussion
When an antimicrobial agent is launched and planned to be used for treating infections in a region, it is important to know first its in vitro activity against clinical relevant pathogens in that region. Before our investigation, there has only been one study in Taiwan, which reported the susceptibility and in vitro activity of doripenem against clinically important bacteria. 15 Since the bacterial isolates used in that study were collected in 2005, 15 there might have been significant changes in drug resistance during this time period. Therefore, we conducted the present study using more contemporary clinical isolates.
The current study demonstrated that doripenem has similar in vitro activity to imipenem and/or meropenem against P. aeruginosa, A. baumannii, and various species of Enterobacteriaceae. However, susceptibility to doripenem in P. aeruginosa was slightly higher than imipenem (87% vs. 85%). In contrast, susceptibility rate of doripenem for A. baumannii was slightly lower compared to imipenem and meropenem (56% vs. 60% and 60%; Table 3 and Table 4 ). This result was similar to prior studies conducted in the United States and worldwide. 21, 22 Doripenem also had a slightly higher susceptibility rate for Enterobacteriaceae (100% vs. 98.5% & 99.5%) compared to imipenem and meropenem (Table 3 and Table 4 ).
For the susceptibility of Enterobacteriaceae to ceftazidime, we applied the new 2010 CLSI criteria. Therefore, we did not test for the presence of ESBL producer. 19 Among the Enterobacteriaceae isolates not susceptible to ceftazidime, the susceptibilities to doripenem, imipenem, meropenem, tigecycline and colistin were still high but the susceptibility rate of ciprofloxacin was only 65%.
This study revealed similar rates of susceptibility to doripenem in P. aeruginosa, A. baumannii, and Enterobacteriaceae compared to previous studies conducted in different countries (87% vs. 77.2e100%, 56% vs. 41.8e75.8%, and 100% vs. 98.5e99.5%, respectively). 8,21e25 Similar trends were also seen in other tested antibiotics. 21e29 Compared to the study conducted by Jean et al, the only study investigated the susceptibilities to doripenem in Taiwan before our study, 15 we found that the MIC 90 s of doripenem and meropenem in P. aeruginosa and A. baumannii were both increased (6 mg/mL and 6 mg/mL vs. 1 mg/ mL and 4 mg/mL, >32 mg/mL and >32 mg/mL vs. 16 mg/mL and 16 mg/mL, respectively). We could not compare the differences in susceptibility rates, because Jean et al did not report these rates in their study. The increase in MIC 90 values might be due to different source of enrolled bacteria (single center vs. multicenter); however, it might be also due to a real increase of drug resistance during this 4-year interval. Increased prevalence of carbapenem resistance among clinical isolates of A. baumannii has been noted recently worldwide. 30 It is necessary to conduct a longitudinal study for continuous monitoring of carbapenem resistance.
The MIC 90 values of carbapenems in Enterobacteriaceae in the study did not increase in comparison to that of Jean et al (0.047 mg/mL vs. 0.06e0.12 mg/mL). This might imply that carbapenem resistance among Enterobacteriaceae remains low and stable in Taiwan, unlike some reports indicating rapid increase of carbapenem resistance in Enterobacteriaceae from Europe and USA. 31 In conclusion, our study revealed that doripenem exerted similar in vitro activity against the tested bacteria compared to imipenem and meropenem. With comparison to the prior study conducted in Taiwan in 2005, the MIC 90 values of doripenem, imipenem, and meropenem have increased in P. aeruginosa and A. baumannii. Longitudinal surveillance to monitor carbapenem resistance trend is needed.
